NCT02817126 (REAL) is a NA clinical trial of Robot-assisted resection in Rectal Carcinoma, sponsored by Fudan University.

Who is sponsoring NCT02817126?

NCT02817126 is sponsored by Fudan University.

What drugs are being tested in NCT02817126?

Interventions in NCT02817126: Robot-assisted resection, Laparoscopic resection.

What condition does NCT02817126 study?

NCT02817126 studies Rectal Carcinoma.

Is NCT02817126 still recruiting?

NCT02817126 is currently status unknown. Last updated 22 March 2022.

Last reviewed 2022-03-22 · How we verify

NCT02817126: REAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer

Status unknown NA Last updated 22 March 2022

What this trial tests

NA trial testing Robot-assisted resection in Rectal Carcinoma in 1,240 participants. Status unknown.

Timeline

10 July 2016

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Fudan University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,240
Start date	10 July 2016
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	11 locations across China

Drugs / interventions tested

Robot-assisted resection
Laparoscopic resection

Conditions studied

Rectal Carcinoma — all drugs for Rectal Carcinoma →

Sponsor

Fudan University

Who can join

Adults 18 to 80, any sex, with Rectal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and oncological feasibility of robot-assisted surgery for mid/low rectal carcinoma compared with laparoscopic surgery.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial.
Feng Q, Yuan W, Li T, Tang B, et al · · 2022 · cited 327× · PMID 36087608 · DOI 10.1016/s2468-1253(22)00248-5
There is no difference in outcome between laparoscopic and open surgery for rectal cancer: a systematic review and meta-analysis on short- and long-term oncologic outcomes.
Pędziwiatr M, Małczak P, Mizera M, Witowski J, et al · · 2017 · cited 55× · PMID 28795243 · DOI 10.1007/s10151-017-1662-4
Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer: The REAL Randomized Clinical Trial.
Feng Q, Yuan W, Li T, Tang B, et al · · 2025 · cited 49× · PMID 40455621 · DOI 10.1001/jama.2025.8123
Robotic Surgery for Rectal Cancer: Hype or Hope? (Indian Experience).
Somashekhar SP, Ashwin KR, Rohit Kumar C. · · 2020 · cited 5× · PMID 33281402 · DOI 10.1007/s13193-020-01113-7
Influence of surgical start time on the quality of surgery for middle and low rectal cancer: a post hoc analysis of the real trial.
He G, Zhang Z, Yuan W, Li T, et al · · 2025 · cited 1× · PMID 40171564 · DOI 10.1097/js9.0000000000002345

Verify or expand the search:

Other recruiting trials for Rectal Carcinoma

Currently open trials in the same condition.

NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT07407647 — Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer · Phase 2 · recruiting
NCT06424522 — A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Canc · NA · recruiting
NCT07283939 — Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · NA · recruiting
NCT06965166 — Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02817126 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 22 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02817126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing